Your browser doesn't support javascript.
loading
The post-finasteride syndrome: possible etiological mechanisms and symptoms.
Leliefeld, Herman H J; Debruyne, Frans M J; Reisman, Yakov.
Afiliação
  • Leliefeld HHJ; Andros Clinics The Netherlands, Wilhelminapark 12, 3581 NC, Utrecht, The Netherlands. hleliefe@kpnmail.nl.
  • Debruyne FMJ; Andros Clinics The Netherlands, Mr. E.N. van Kleffenstraat 5, 6842 CV, Arnhem, The Netherlands.
  • Reisman Y; Flare-Health, Oosteinderweg 348, 1432 BE, Aalsmeer, The Netherlands.
Int J Impot Res ; 2023 Sep 11.
Article em En | MEDLINE | ID: mdl-37697052
ABSTRACT
Finasteride and dutasteride, synthetic 5α-reductase inhibitors (5ARIs) are recommended in many guidelines for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms and alopecia despite a variety of side effects like sexual, neurological, psychiatric, endocrinological, metabolic and ophthalmological dysfunctions and the increased incidence of high grade prostate cancer. The sexual side effects are common during the use of the drug but in a small subgroup of patients, they can persist after stopping the drug. This so-called post-finasteride syndrome has serious implications for the quality of life without a clear etiology or therapy. Three types of 5α-reductases are present in many organs in- and outside the brain where they can be blocked by the two 5ARIs. There is increasing evidence that 5ARIs not only inhibit the conversion of testosterone to 5α-dihydrotestosterone (DHT) in the prostate and the scalp but also in many other tissues. The lipophilic 5ARIs can pass the blood-brain barrier and might block many other neurosteroids in the brain with changes in the neurochemistry and impaired neurogenesis. Further research and therapeutic innovations are urgently needed that might cure or relieve these side effects. More awareness is needed for physicians to outweigh these health risks against the benefits of 5ARIs.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article